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INTRODUCTION
Gastrointestinal acute variceal bleeding (AVB) is a seri-
ous complication in cirrhotic patients with portal hyper-
tension with a high related mortality.1,2 Besides
hemodynamic resuscitation with crystalloids and packed
red blood cell (PRBC) transfusion, current practice
guidelines recommend the combination of vasoactive
drugs and endoscopic therapy (ET), in addition to the use
of prophylactic antibiotics as standard treatment for
AVB.3-7 The vasoactive drugs, terlipressin, somatostatin,
and octreotide are a standard of care for the control of
AVB in patients with cirrhosis by reducing portal blood
flow and portal pressure.8,9 These drugs have been associ-
ated with a lower risk of mortality as well as improved
control of bleeding.10
The main determinant of AVB-related mortality is
functional hepatic reserve. Child-Pugh class A (CP-A) pa-
tients have negligible mortality, whereas CP class C (CP-
C) patients have a mortality rate between 20-32%.2,11 We
previously reported the characteristics and outcomes of
212 patients with AVB in a 4-year period in our center. All
patients received ET and antibiotic prophylaxis. Only a
minority of patients (9.0%) received vasoactive drugs (oc-
treotide) with no deaths reported in the subset of patients
with CP-A.12
Vasoactive drugs are recommended to be started as
soon as possible in suspected variceal bleeding, even be-
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A B S T R A C T
Background. Current guidelines do not differentiate in the utilization of vasoactive drugs in patients with cirrhosis and acute
variceal bleeding (AVB) depending on liver disease severity. Material and methods. In this retrospective study, clinical out-
comes in 100 patients receiving octreotide plus endoscopic therapy (ET) and 216 patients with ET alone were compared in terms of
failure to control bleeding, in-hospital mortality, and transfusion requirements stratifying the results according to liver disease severity
by Child-Pugh (CP) score and MELD. Results. In patients with CP-A or those with MELD < 10 octreotide was not associated with
a better outcome compared to ET alone in terms of hospital mortality (CP-A: 0.0 vs. 0.0%; MELD < 10: 0.0 vs. 2.9%, p = 1.00),
failure to control bleeding (CP-A: 8.7 vs. 3.7%, p = 0.58; MELD < 10: 5.3 vs. 4.3%, p = 1.00) and need for transfusion (CP-A: 39.1
vs. 61.1%, p = 0.09; MELD < 10: 63.2 vs. 62.9%, p = 1.00). Those with severe liver dysfunction in the octreotide group showed bet-
ter outcomes compared to the non-octreotide group in terms of hospital mortality (CP-B/C: 3.9 vs. 13.0%, p = 0.04; MELD ? 10:
3.9 vs. 13.3%, p = 0.03) and need for transfusion (CP-B/C: 58.4 vs. 71.6%, p = 0.05; MELD ? 10: 50.6 vs. 72.7%, p < 0.01). In
multivariate analysis, octreotide was independently associated with in-hospital mortality (p = 0.028) and need for transfusion (p =
0.008) only in patients with severe liver dysfunction (CP-B/C or MELD ? 10). Conclusion. Patients with cirrhosis and AVB cate-
gorized as CP-A or MELD < 10 had similar clinical outcomes during hospitalization whether or not they received octreotide.
Key words. Octreotide. Cirrhosis. Portal hypertension. Variceal hemorrhage. Vasoactive drugs.
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fore diagnostic endoscopy. However, there are no studies
specifically addressing the benefits of vasoactive drugs in
patients with ET depending on their baseline liver func-
tion. Furthermore, current recommendations for manage-
ment of AVB do not differ for patients with different
functional hepatic reserve. The use of these vasoactive
drugs carries a risk of side effects and increases the cost of
medical care. These considerations suggest that patients
might benefit from a stratified approach to treatment, tak-
ing into account the baseline risk of the patient. Indeed,
the Baveno VI workshop was entitled “Stratifying risk and
individualizing care for portal hypertension”. Thus, the
aims of this retrospective comparative study was to ana-
lyze the failure to control bleeding, hospital mortality and
transfusion requirements among patients with AVB ac-
cording to their functional hepatic reserve assessed by the
CP score and the Model for End-stage Liver Disease
(MELD).
MATERIAL AND METHODS
This was a comparative, retrospective, observational
study. The medical records of patients with liver cirrhosis
presenting at our “Dr. José E. González” University Hos-
pital with AVB were reviewed from June 2009 to July 2015.
We compared two groups of patients, those receiving
combined therapy (ET plus octreotide) and those receiv-
ing ET alone. The determinant for octreotide treatment
was whether it was covered by the patient social insurance
or, if that not was the case, if the patient had means to pay
for the drug. Somatostatin and terlipressin were not used
in our patients because the former is not available in our
country and the latter is not covered by the patients' social
insurance.
Approval was obtained from the research and ethics
committee of the School of Medicine and the “Dr. José E.
González” University Hospital of the Universidad Au-
tónoma de Nuevo León. The study was performed in
compliance with the Declaration of Helsinki for biomed-
ical research. Informed consent was obtained from all par-
ticipants for the diagnostic and therapeutic maneuvers
required in each case.
The reviewed medical records were included for analy-
sis if they fulfilled the following inclusion criteria:
• Patient aged 18 years or older.
• Liver cirrhosis diagnosed by compatible clinical, labo-
ratory, and radiologic findings or previous liver biopsy.
• Endoscopy performed within the 24 h of hospital ad-
mission with confirmed AVB treated with endoscopic
variceal ligation (EVL) or cyanoacrylate.
• Prophylactic antibiotics were administered at admis-
sion or immediately after AVB was confirmed.
• In the group of patients receiving octreotide, this had
to be administered within the first 24 h of admission.
The octreotide was administered initially at a 50 ?g in-
travenous bolus dose and continued an intravenous infu-
sion at 50 ?g/h at least for 2 to 5 days. Patients medical files
were excluded if they presented any of the following that
might work as confounding factors:
• Non-cirrhotic portal hypertension.
• A history of endoscopic variceal therapy within 2
weeks before the episode.
• Patients with other evident source of bleeding differ-
ent to esophageal or gastric varices.
• Insufficient or confusing clinical data from the medi-
cal records regarding the primary outcomes.
General characteristics (age, gender, etiology of cirrho-
sis), laboratory and clinical variables were recorded. Liver
function at admission was assessed using the CP score and
MELD. The CP score was determined using the classical
parameters: ascites, encephalopathy, serum albumin, total
bilirubin and prothrombin time. The patients were classi-
fied as CP-A (5-6 points), CP-B (7-9 points) and CP-C (?
10 points).13 The MELD score was calculated using the
following formula: 3.8 log e (serum bilirubin mg/dL) +
11.2 log e (INR) + 9.6 log e (serum creatinine mg/dL) +
6.4.13
During hospital stay, the following outcomes were re-
corded: 5-day failure to control bleeding, in-hospital mor-
tality, PRBC transfusion requirements, survival without
rebleeding and length of hospital stay.
Definitions
Time zero (T0) was defined as the time of hospital ad-
mission. Failure to control bleeding was defined as any
occurrence of fresh hematemesis or recurrent melena (af-
ter passing normal stools) resulting in a 3 g drop in hemo-
globin (9% drop of hematocrit) or need for transfusion.
In-hospital mortality was defined as death from any cause
during hospitalization. Survival without rebleeding was
defined as the control of AVB without rebleeding or death.
Need for transfusion was defined as the requirement of at
least one PRBC transfusion from any cause during hospi-
tal stay. Hospital stay length was defined as the period of
time in days from T0 to discharge or death.
Study aims
The primary aim was to determine the effect of using
or not octreotide in the 5-day failure to control bleeding,
hospital all-cause mortality and the need for transfusion in
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patients with cirrhosis and AVB treated endoscopically de-
pending on their functional hepatic reserve measured by
CP score or MELD.
Secondary objectives were to determine the effect of
using or not octreotide in survival without rebleeding, and
hospital stay length between the octreotide and non-octre-
otide groups. Also, to compared the general and clinical
variables between patients according to 5-day control of
bleeding and hospital mortality.
Statistical analysis
Statistical analyses were performed with SPSS 20.0
(IBM, Armonk, NY, USA). Baseline characteristics of pa-
tients in both groups with and without octreotide were
compared with the use of Student’s t-test or the Mann-
Whitney test for continuous variables and Fisher’s exact
test for categorical variables, as appropriate. Data are pre-
sented as absolute value and percentages, mean and stand-
ard deviation (SD) or median and interquartile range
(IQR) as appropriate. The relationship between the differ-
ent variables and the risk of developing the endpoints
were analyzed by logistic regression. The contribution of
each variable to the risk of developing the endpoint is re-
ported as the odds ratio (OR) with 95% confidence inter-
val (CI). Multivariate logistic regression models were
used to calculate adjusted probabilities (aOR) of 5-day
failure to control bleeding, in-hospital mortality and need
for transfusion within each CP and MELD strata.
RESULTS
Patient characteristics
The medical records of three-hundred and sixteen pa-
tients were retrospectively searched. Of the 316 patients,
100 were treated with ET plus octreotide (octreotide
group) and 216 were treated with ET alone (non-octre-
otide group). All patients received prophylactic antibiotics
at admission or immediately after AVB was confirmed.
The study population was male dominant (70.9%) with a
median age of 53.2 ± 12.4 years. Alcoholic liver disease
(57.9%) was the most common cause of liver cirrhosis.
Baseline characteristics of patients did not differ signifi-
cantly between the two treatment groups (Table 1). There
were no missing data for the variables of interest.
Impact of octreotide on the risk of
failure to control bleeding
The 5-day failure to control bleeding between groups
was 7.0% in the octreotide group compared to 6.9% in the
non-octreotide group, p = 1.000. No differences were ob-
served in any strata defined by CP or MELD (Table 2).
Table 1. Baseline characteristics of patients with acute variceal bleeding according to type of treatment.
Characteristics Total Octreotide Non-octreotide
n = 316 n = 100 n = 216 P
Age, years 53.2 ± 12.4 52.2 ± 12.0 53.6 ± 12.6 0.338
Gender (M/F) - n 224/92 73/27 151/65 0.597
Etiology of cirrhosis 0.375
Alcohol - n (%) 183 (57.9) 61 (61.0) 123 (56.5) 0.465
Viral - n (%) 23 (7.3) 10 (10.0) 13 (6.0) 0.245
NASH - n (%) 4 (1.3) 1 (1.0) 3 (1.4) 1.000
Autoimmune hepatitis - n (%) 13 (4.1) 5 (5.0) 8 (3.7) 0.558
PBC - n (%) 4 (1.3) 2 (2.0) 2 (0.9) 0.594
Unknown & Cryptogenic - n (%) 89 (28.2) 21 (21.0) 68 (31.5) 0.060
Child-Pugh score, points 8.0 ± 2.0 8.0 ± 1.9 8.0 ± 2.0 0.927
MELD, points 13.7 ± 7.1 14.7 ± 6.2 13.2 ± 7.4 0.091
Child-Pugh Class 0.907
Child A - n (%) 77 (24.4) 23 (23.0) 54 (25.0) 0.779
Child B - n (%) 176 (55.7) 56 (56.0) 120 (55.6) 1.000
Child C - n (%) 63 (19.9) 21 (21.0) 42 (19.4) 0.763
Type of varices 0.927
Esophageal or GOV - n (%) 304 (96.2) 96 (96.0) 208 (96.4)
IGV type I - no. (%) 12 (3.8) 4 (4.0) 8 (3.6)
Data are shown as absolute value (%) and means ± standard deviation. Both treatment groups received endoscopic therapy. Virus category includes patients
with viral hepatitis alone and patients with viral hepatitis and alcohol. NASH: Non-alcoholic steatohepatitis. PBC: Primary biliary cholangitis. MELD: Model for
End-stage Liver Disease. GOV: Gastroesophageal varices. IGV: Isolated Gastric Varices.
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Impact of octreotide
on the risk of hospital mortality
Overall, patients in the octreotide group had a lower
hospital mortality compared with those not receiving oc-
treotide, 3.0% vs. 9.7% (p = 0.04) (Table 2). Mortality in
CP-A patients and in patients with a MELD below 10 was
negligible and not impacted by octreotide treatment (CP-
A: 0.0 vs. 0.0%; and MELD < 10: 0.0 vs. 2.9%, p = 1.00).
Those with severe liver dysfunction in the octreotide
group presented lower hospital mortality than those in the
non-octreotide group (Table 2).
Univariate analysis showed that octreotide was associ-
ated with a decreased risk of mortality (Table 3, OR 0.287,
95% CI 0.084-0.986; p = 0.048). This association between
octreotide treatment and survival remained significant at
multivariate analysis (Table 4: aOR 0.179, 95% CI 0.044-
0.735; p = 0.017). The predicted hospital mortality in oc-
treotide and non-octreotide groups across the spectrum of
CP score and MELD showed that the benefit of using oc-
treotide was observed in patients with CP-B/C and in pa-
tients with MELD ? 10 (Figure 1). Subanalysis by CP and
MELD strata showed in multivariate analysis that only in
Table 2. Outcomes in patients with and without octreotide, in the overall series and in different subgroups.
Octreotide Non-octreotide
Characteristics  n (%) n (%) P
5-day failure to control bleeding 7 (7.0) 15 (6.9) 1.000
Child A 2 (8.7) 2 (3.7) 0.578
Child B 3 (5.4) 7 (5.8) 1.000
Child C 2 (9.5) 6 (14.3) 0.708
Child B/C 5 (6.5) 13 (8.0) 0.797
MELD < 10 pts 1 (5.3) 3 (4.3) 1.000
MELD ? 10 pts 6 (7.8) 12 (8.4) 1.000
In-hospital mortality 3 (3.0) 21 (9.7) 0.040
Child A 0 0 -
Child B 1 (1.8) 7 (5.8) 0.439
Child C 2 (9.5) 14 (33.3) 0.064
Child B/C 3 (3.9) 21 (13.0) 0.037
MELD < 10 pts 0 (0.0) 2 (2.9) 1.000
MELD ? 10 pts 3 (3.9) 19 (13.3) 0.033
Survival without rebleeding 91 (91.0) 188 (87.0) 0.352
Child A 21 (91.3) 52 (96.3) 0.578
Child B 52 (92.9) 108 (90.0) 0.779
Child C 18 (85.7) 28 (66.7) 0.139
Child B/C 70 (90.9) 136 (84.0) 0.165
MELD < 10 pts 18 (94.7) 65 (92.9) 1.000
MELD ? 10 pts 69 (89.6) 120 (83.9) 0.311
Need for transfusion 54 (54.0) 149 (69.0) 0.012
Transfusions (n) 1.0 (2.0) 2.0 (3.0) 0.003
Child A 9/23 (39.1) 33/54 (61.1) 0.087
Transfusions (n), units (median [IQR]) 0.0 (1.0) 1.0 (3.0) 0.029
Child B 33/56 (58.9) 86/120 (71.7) 0.119
Transfusions (n), units (median [IQR]) 1.0 (2.0) 2.0 (3.0) 0.108
Child C 12/21 (57.1) 30/42 (71.4) 0.273
Transfusions (n), units (median [IQR]) 1.0 (2.0) 2.0 (4.0) 0.078
Child B/C 45/77 (58.4) 116/162 (71.6) 0.055
Transfusions (n), units (median [IQR]) 1.0 (2.0) 2.0 (3.0) 0.021
MELD < 10 pts 12/19 (63.2) 44/70 (62.9) 1.000
No. of transfusions, units (median [IQR]) 2.0 (3.0) 2.0 (3.0) 0.860
MELD ? 10 pts 39/77 (50.6) 104/143 (72.7) 0.002
Transfusions (n), units (median [IQR]) 1.0 (2.0) 2.0 (3.0) < 0.001
Hospital stay, days 4.0 (2.0) 5.0 (2.0) 0.225
Bold numbers represent statistical significance. MELD: Model for End-stage Liver Disease. IQR: Interquartile range.
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those with severe liver disease (CP-B/C or MELD ? 10)
octreotide use was associated with an improved prognosis
(Table 4).
Impact of octreotide
on the need for transfusion
The proportion of patients needing transfusion was
54.0% in the octreotide group compared to 69.0% in the
non-octreotide group (p = 0.012). The median number
(IQR) of PRBC units transfused was 1.0 (2.0) in the octre-
otide group and 2.0 (3.0) in the non-octreotide group (p =
0.003). In univariate analysis, octreotide was the only factor
independently associated with the need for transfusion
(Table 3: OR 0.528, 95% CI 0.324-0.860; p = 0.010).
Patients with CP-A as well as those with MELD < 10
in the non-octreotide group presented no significant dif-
ference compared with those in the octreotide group in
the need for transfusion (Table 2). When we compared the
number of transfusions between groups based in the base-
line hepatic function by CP class and MELD, there was
some significant difference (Table 2). However, octre-
otide was not independently associated with the need for
transfusion of 2 or more PRBC units in the subgroup of
patients with CP-A (OR 0.272, 95% CI 0.056-1.312; p =
0.105) and MELD below 10 (OR 1.192, 95% CI 0.414-
3.431; p = 0.745). Moreover, among those with severe liv-
er disease, octreotide was a protective factor
independently associated with the need for transfusion of
2 or more PRBC units (CP-B/C: OR 0.496, 95% CI 0.262-
0.940; p = 0.032; and MELD ? 10: OR 0.270, 95% CI
0.124-0.588; p = 0.001). In addition as shown in table 4,
the need for transfusion was only modified by octreotide
in the subgroup of patients with severe liver disease (CP-
B/C or MELD ? 10).
Secondary analysis
No difference in survival without rebleeding and in-
hospital stay length between the octreotide and non-octre-
otide groups either in the overall analysis or by stratifying
patients according to the CP class or MELD was found (p
> 0.05). We also compared the general and clinical varia-
bles between patients according to 5-day control of bleed-
ing, and in-hospital mortality (Table 5). At univariate
analysis, both CP score and MELD predicted failure to
control bleeding and mortality (Table 3); in multivariate
analysis CP score and MELD were independently associ-
ated only to the mortality outcome (Table 4).
DISCUSSION
The combination of vasoactive agents with EVL is stand-
ard therapy for AVB,9,10,14-18 but it is still uncertain if all pa-
tients need vasoactive treatment or if this could be avoided
in low-risk patients. This is especially relevant in environ-
ments in which access to drug therapy is limited by its cost.
In this study, we have shown that the probability of failure
Figure 1. Predicted mortality in patients with cirrhosis treated or not with octreotide across different Child-Pugh score or MELD. These predictions were
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to control bleeding, mortality and need for transfusion dur-
ing hospitalization in CP-A or MELD < 10 patients was
very low regardless of whether they received or not octre-
otide. Patients with severe liver dysfunction (CP-B/C or
MELD ? 10) in the octreotide group showed better out-
comes compared to patients not receiving octreotide in
terms of mortality and PRBC transfusion requirements.
The current recommendations of using combined ther-
apy of vasoactive drugs and ET in the setting of AVB, lies
on the evidence provided by studies that assessed the 5-
day success rate.14,15,18,19 However, most of these studies
used endoscopic sclerotherapy which is inferior to EVL;20
in addition, they did not stratify outcomes based on the
grade of liver disease severity.
Several studies have shown that combination therapy
improves control of bleeding compared with ET alone,
though the effect in survival is still controversial.9,10,14-18
In addition there is little information on whether patients
with preserved liver function (CP-A or MELD < 10),
who are at very low risk of treatment failure benefit from
combination therapy. In agreement with our results, Ber-
reta, et al. reported 0% mortality in both treatment groups
Table 3. Univariate analysis for primary clinical outcomes in cirrhotic patients with acute variceal bleeding.
Outcomes
Risk Factors Failure to control In-hospital mortality Need for
bleeding transfusion
Overall analysis OR 95% CI P OR 95% CI P OR 95% CI P
Age, years 1.014 0.979-1.049 0.434 1.008 0.975-1.042 0.631 1.007 0.988-1.026 0.463
Gender (male) 0.700 0.283-1.730 0.440 1.252 0.481-3.263 0.645 0.822 0.492-1.373 0.454
Etiology of cirrhosis 0.641 0.589 0.216
CP score 1.282 1.051-1.564 0.014 1.816 1.487-2.330 < 0.001 1.056 0.938-1.189 0.367
MELD 1.074 1.024-1.127 0.004 1.154 1.097-1.214 < 0.001 0.990 0.958-1.023 0.548
Octreotide 1.009 0.398-2.557 0.986 0.287 0.084-0.986 0.048 0.528 0.324-0.860 0.010
Hospital stay, days 1.002 0.913-1.143 0.708 0.994 0.878-1.126 0.930 0.974 0.912-1.039 0.420
Bold numbers represent statistical significance. CP score and MELD: The risk for the occurrence of clinical outcomes increase per point. CP: Child-Pugh.
MELD: Model for End-stage Liver Disease. OR: Odds Ratio. CI: Confidence interval.
Table 4. Multivariate analysis for primary clinical outcomes in cirrhotic patients with acute variceal bleeding.
Risk Factors Outcomes
Failure to control bleeding In-hospital mortality Need for transfusion
aOR 95% CI P aOR 95% CI P aOR 95% CI P
Overall analysis
CP score 1.144 0.900-1.455 0.271 1.632 1.255-2.121 < 0.001 NA NA NA
MELD 1.055 0.996-1.118 0.069 1.108 1.046-1.173 < 0.001 NA NA NA
Octreotide NA NA NA 0.179 0.044-0.735 0.017 0.528 0.324-0.860 0.010
Subgroup analysis
CP-A or MELD < 10 (n = 124)
CP score 1.116 0.656-1.900 0.685 3.324 1.194-9.253 0.022 NA NA NA
MELD 1.038 0.781-1.380 0.797 1.414 0.689-2.904 0.345 NA NA NA
Octreotide NA NA NA NA* NA* NA* 0.655 0.297-1.440 0.292
CP-B/C or MELD ? 10 (n = 192)
CP score 1.194 0.888-1.605 0.240 1.484 1.117-1.972 0.006 NA NA NA
MELD 1.063 0.996-1.135 0.066 1.113 1.045-1.185 0.001 NA NA NA
Octreotide NA NA NA 0.207 0.051-0.844 0.028 0.418 0.220-0.794 0.008
Bold numbers represent statistical significance. CP score and MELD: The risk for the occurrence of clinical outcomes increase per point. CP: Child-Pugh.
MELD: Model for End-stage Liver Disease. aOR: adjusted Odds Ratio. CI: Confidence interval. NA: Not applicable. * There were no recorded deaths in the
octreotide group in patients classified as CP-A or MELD < 10, so it was not possible to calculate the adjusted risk by multivariate logistic regression.
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(combined therapy vs. ET alone) in the subset of patients
with CP-A.21 They showed that the benefit of using com-
bined therapy was the reduction of initial hemostatic fail-
ure and rebleeding in the CP-C group and those
presenting with active bleeding. In a previous study, our
group also reported 0% mortality in patients with CP-A
even though only a very small proportion of patients in
that study received octreotide.12
A previous randomized placebo-controlled double-
blind study comparing endoscopic variceal sclerotherapy
alone and in combination with octreotide in patients with
low-risk cirrhosis (excluding patients with refractory as-
cites, CP-C, and chronic encephalopathy) and AVB re-
ported a significant difference in the rate of 5-day
rebleeding, a shorter hospital stay and number of PRBC
units transfused in the combined treatment group.22 How-
ever, even though this study focused on a group of low-
risk cirrhotic patients, it did not differentiate between
very low-risk CP-A and CP-B patients, and the study did
not provide data stratifying by MELD. In addition, due to
the small number of patients and since just one patient
from each group died during the study, they were not able
to provide conclusions regarding mortality. Another rand-
omized placebo-controlled double-blind study reported a
significantly higher rate of “survival without rebleeding” at
five days in all three CP classes with combined therapy as
compared with monotherapy alone; however, mortality
was unaffected;17 octreotide was also associated with an
overall reduction in transfusion requirements; however,
these results were not analyzed stratifying patients accord-
ing to CP class and MELD.17 In a trial comparing sclero-
therapy plus somatostatin versus sclerotherapy alone,
Avgerinos, et al. reported an improvement in the overall 5-
day failure of therapy (defined as any of the following:
transfusion of an excess of blood products; hematemesis;
hemodynamic instability; use of rescue therapy; or death)
with combination therapy in overall analysis (35 vs. 55%, p
= 0.004), as well as in the subset of patients with a CP-A (2
patients vs. 9 patients, p = 0.021).18 However, they do not
report specific mortality data in the CP-A subgroup; in ad-
dition, the number of CP-A patients was small. Despite
the retrospective nature of our study, we collected 124 pa-
tients with very low risk (CP-A or MELD < 10) which
greatly exceeds the number of low-risk patients as com-
pared to previous reports.12,18,22
Because mortality in CP-A patients with AVB has been
reported to be 0%,2,11,21 which is in accordance with our
results, we speculate that this very low risk subgroup of
patients (CP-A or MELD < 10) may have a better hemo-
dynamic adaptation response to an episode of AVB with no
additional benefit from the splanchnic vasoconstrictor
properties of vasoactive drugs. These variations in the
physiopathological mechanisms with respect to vascular
hemodynamics have already been proven to vary depend-
ing on the severity of liver disease.23-27
One surprising finding in our study was that octreotide
had no impact on control of bleeding but still showed a
positive effect in terms of mortality and transfusion re-
quirements. Since most of our patients were endoscopi-
cally treated with EVL (> 95%), the most likely
explanation is that EVL is a highly effective method for he-
mostasis, at least within the first five days of admission.
This is supported by the data from a meta-analysis demon-
strating that EVL is superior in control bleeding compared
Table 5. Comparison of general and clinical variables between patients according to control of bleeding and hospital mortality.
Characteristics No rebleeding Rebleeding OR P Alive Dead OR P
n = 294 n = 22 (95% CI) n = 292 n = 24 (95% CI)
Age, 53.0 ± 12.5 55.1 ± 10.2 1.01 0.439 53.1 ± 12.5 54.3 ± 11.4 1.01 0.631
years mean ± SD (0.98-1.05) (0.97-1.04)
Gender (M/F) - n 210/84 14/8 0.70 0.440 206/86 18/6 1.25 0.645
(0.28-1.73) (0.48-3.26)
Etiology of cirrhosis 0.641 0.589
CP score, 7.9 ± 1.9 9.0 ± 2.4 1.28 0.014 7.7 ± 1.8 10.5 ± 2.2 1.82 < 0.001
points mean ± SD (1.05-1.56) (1.49-2.33)
MELD, 13.3 ± 6.7 18.1 ± 9.9 1.07 0.004 12.9 ± 6.1 23.1 ± 10.0 1.15 < 0.001
points mean ± SD (1.02-1.13) (1.10-1.21)
Transfusions (n), 2.0 (3.0) 1.5 (3.2) 1.06 0.621 1.0 (3.0) 2.0 (4.7) 1.25 0.044
units (median [IQR]) (0.83-1.36) (1.01-1.55)
Hospital stay, days 5.0 (2.0) 4.0 (3.0) 1.02 0.708 5.0 (1.7) 3.0 (5.7) 0.99 0.930
(median [IQR]) (0.91-1.14) (0.89-1.13)
Bold numbers represent statistical significance. Data are shown as absolute value and means ± SD or median (IQR) as indicated. CP: Child-Pugh. MELD:
Model for End-stage Liver Disease. OR: Odds ratio. CI: Confidence interval. SD: Standard deviation. IQR: Interquartile range.
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to sclerotherapy.20 In addition, in accordance with our re-
sults, a recent randomized controlled trial comparing EVL
plus somatostatin infusion versus EVL plus placebo did
not find any advantage in control of AVB at 5 days.28 How-
ever, confounders we could not reliably capture (i.e. the
incidence of spontaneous bacterial peritonitis or septic
complications) could be a posible explanation for the dif-
ference in mortality in this retrospective review.
Due to the inconclusive evidence related to the cost-ef-
fectiveness of vasoactive drugs in AVB in patients catego-
rized as “very low risk”, studies with a six-week follow-up
comparing the cost-effectiveness of combined therapy (ET
+ terlipressin, somatostatin or octreotide) with ET alone
are crucial before to give a recommendation in this sub-
group of patients. However, the strengths of this study lies
in the fact that we provide thorough data on CP and MELD
stratified patients and the benefits of using octreotide in
AVB in a large number of patients treated with EVL. The
only determinant of octreotide treatment was the socioeco-
nomic status of the patients, which determined whether
they could pay or not for the drug. Thus, the clinical base-
line characteristics were comparable between groups treat-
ed or non-treated with octreotide.
A limitation of our study is the potential indication bias
introduced by octreotide treatment. Though the strongest
prognostic determinant in AVB is the baseline liver func-
tion,29,30 the determinants for the use of octreotide might
have introduced unknown bias that could not be account-
ed for in the multivariate analysis. Also, though we adjust-
ed the effects of octreotide by the most relevant predictors
in a multivariate analysis, there might be residual con-
founding not captured by the standard variables that were
collected in our study (e.g. cardiovascular comorbidities,
history of prior variceal bleedings, portal vein thrombo-
sis, hepatocarcinoma, etc).
In summary, this study presents the benefits of octre-
otide in patients with cirrhosis presenting with AVB ac-
cording to liver disease severity by CP score and MELD.
Patients with cirrhosis and preserved liver function (CP-A
or MELD < 10) presenting with AVB may not benefit
from octreotide during hospitalization in terms of failure
to control bleeding, mortality and the need for transfu-
sion.
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ABBREVIATIONS
• aOR: adjusted odds ratio.
• AVB: Acute variceal bleeding.
• CI: Confidence interval.
• CP: Child-Pugh.
• CP-A: Child-Pugh class A.
• CP-B: Child-Pugh class B.
• CP-C: Child-Pugh class C.
• ET: Endoscopic therapy.
• EVL: Endoscopic variceal ligation.
• IQR: Interquartile range.
• MELD: Model for End-stage Liver Disease.
• OR: Odds ratio.
• PRBC: Packed red blood cell.
• SD: Standard deviation.
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